Analysts predict that Genocea Biosciences, Inc. (NASDAQ:GNCA) will announce earnings per share (EPS) of ($0.46) for the current quarter, according to Zacks. Zero analysts have made estimates for Genocea Biosciences’ earnings. The lowest EPS estimate is ($0.50) and the highest is ($0.40). Genocea Biosciences posted earnings per share of ($0.39) during the same quarter last year, which indicates a negative year-over-year growth rate of 17.9%. The company is scheduled to report its next quarterly earnings results on Thursday, August 3rd.

According to Zacks, analysts expect that Genocea Biosciences will report full-year earnings of ($1.87) per share for the current fiscal year, with EPS estimates ranging from ($2.13) to ($1.70). For the next fiscal year, analysts expect that the company will report earnings of ($2.07) per share, with EPS estimates ranging from ($2.51) to ($1.44). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Genocea Biosciences.

Genocea Biosciences (NASDAQ:GNCA) last posted its earnings results on Thursday, May 4th. The biotechnology company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.06.

Separately, Zacks Investment Research lowered shares of Genocea Biosciences from a “buy” rating to a “hold” rating in a research report on Monday, June 5th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $16.02.

COPYRIGHT VIOLATION NOTICE: This article was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/06/20/brokerages-anticipate-genocea-biosciences-inc-gnca-will-announce-earnings-of-0-46-per-share.html.

Genocea Biosciences (NASDAQ:GNCA) opened at 5.15 on Tuesday. Genocea Biosciences has a 1-year low of $3.28 and a 1-year high of $7.29. The stock’s market cap is $146.79 million. The stock has a 50 day moving average of $6.01 and a 200 day moving average of $5.30.

A number of large investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its stake in Genocea Biosciences by 4.7% in the first quarter. Geode Capital Management LLC now owns 148,370 shares of the biotechnology company’s stock valued at $903,000 after buying an additional 6,708 shares in the last quarter. Vanguard Group Inc. raised its stake in Genocea Biosciences by 11.4% in the first quarter. Vanguard Group Inc. now owns 751,972 shares of the biotechnology company’s stock valued at $4,579,000 after buying an additional 77,052 shares in the last quarter. Segantii Capital Management Ltd purchased a new stake in Genocea Biosciences during the first quarter valued at about $160,000. FMR LLC raised its stake in Genocea Biosciences by 0.4% in the first quarter. FMR LLC now owns 4,274,804 shares of the biotechnology company’s stock valued at $26,033,000 after buying an additional 18,574 shares in the last quarter. Finally, JPMorgan Chase & Co. purchased a new stake in Genocea Biosciences during the first quarter valued at about $217,000. 54.20% of the stock is owned by institutional investors.

Genocea Biosciences Company Profile

Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.

Get a free copy of the Zacks research report on Genocea Biosciences (GNCA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.